Whole Genome Sequencing (WGS) Long Read Instruments & Consumables

Tender description

The supply of instruments and consumables that provides a solution to enable investigations into methylation (5mC,5hmC), structural variant calling, copy number variant analysis and single nucleotide polymorphisms (SNP) detection, using native DNA sequencing for up to 3000 Diversity participant samples and 1000 Cancer participant samples. Lot 1: Genomics England (GEL) wants to explore long-read and methylation sequencing in cancer within the NHS and accurately to sequence genomes of under-represented and diverse ancestries with a view that this novel technology could open opportunities to identify not only known genomic features and aberrations but also those that are currently unidentifiable using existing sequencing technologies. This could facilitate immediate returns in diagnostic value to the NHS and reaping more meaningful rewards in the near future through more thorough analysis of the whole genome. Long-read analytical methods are still in their infancy, GEL is building a knowledge hub around the trusted research environment for individuals to train their methods; in turn these methods feed into the clinical pipeline of the future. Nurturing the research environment will permit the discovery of new diagnostic and prognostic markers as well as potential new targets for drug discovery to benefit patients in the future. GEL has a requirement to purchase Long Read sequencing technology to fulfil its needs in relation to the Cancer and Diversity Programmes. The requirement is to provide sufficient sequencing instruments and necessary consumables and kit to meet the current and forecasted need at GEL's Hinxton Lab and at 3 GLH sites for FY 22/23. The requirement also includes appropriate support & maintenance and licenses required for operation. The anticipated forecast is set at 3000 Diversity participant samples and 1000 Cancer participant samples in this period. There will be an optional requirement within the contract to provide sufficient instruments and consumables for up to a further 1000 Diversity participants and 500 Cancer participants to meet additional unplanned demand. There is no guarantee or warranty that the optional requirements will be purchased and tender responses relating to such optional requirements will not be evaluated.